Fundamentals · DHR
Peer Comparison for DHR
AI-generated plain-English read of peer comparison for DHR. Updated daily.
Premium vs peers, in-line growth
moderateDHR trades at 1.37x the sector median, but its superior fundamentals explain most of the premium: this is pricing quality, not irrational exuberance.
What will probably happen
- Premium names with justified multiples tend to hold their valuation through earnings cycles; the risk is an execution miss, not fundamental deterioration.
- Watch estimate revisions closely: any guidance cut on growth or margin compresses a premium multiple faster than an in-line stock.
What to do
- If you HOLD this stock
- Premium is justified by best-in-class fundamentals. The risk is execution disappointment: any growth miss will compress the multiple sharply. Hold but watch quarter-end estimate revisions tightly.
- If you're EVALUATING this stock
- Quality at a price; reasonable to enter on macro-driven pullbacks rather than chasing peak multiples.
- If you trade OPTIONS
- Sell call premium against shares (covered calls); IV is typically rich on premium-multiple names. Collect premium while the multiple consolidates.
10 peers and 2 valuation metric(s): sufficient but not robust. Treat directional buckets as indicative rather than definitive.
Technical details
Technical analysis
- Sector
- Life Sciences Tools & Services
- Peer count
- 10
- Target P/E
- 36.6x
- Outlier flag
- Structural
- Growth ranking
- In Line Growth
- Peer median P/E
- 26.7x
- Profitability rank
- Above Avg Prof
- Relative valuation
- Premium
- Relative multiple (target / peer median)
- 1.37x
Key levels
| Level | Value |
|---|---|
| n peers | 10 |
| target pe | 36.553 |
| peer median pe | 26.707 |
| valuation ratio | 1.369 |
Caveats
- Peer comparisons are a single-snapshot read. Multi-quarter trends often matter more than current-quarter relative levels.